Vandetanib alters the tumoricidal capacity of human breast cancer stem cells via inhibiting vasculogenic capacity

Sanya Haiaty ^1,2,3,4 , Mohammad-Reza Rashidi ¹, Maryam Akbarzadeh ^1,5, Ahad Bazmany ^6,3, Mostafa Mostafazadeh ², Saba Nikanfar ², Roya Shabkhizan ⁷, Rostam Rezaeian ³, Reza Rahbarghazi ^8,9 * , Mohammad Nouri ^1,2,8

Cited by CrossRef: 2

1- Weng J, Shan Y, Chang Q, Cao C, Liu X. Research progress on N6-Methyladenosine modification in angiogenesis, vasculogenic mimicry, and therapeutic implications in breast cancer. Progress in Biophysics and Molecular Biology. 2025;195:57 [Crossref]

2- Liu X, Chen X, Wang J, He L, Yin S, Chen L, Tang Y, Zheng X, Nie M. Analysis of tumor stem cell recruitment and integration in microvascular architectural heterogeneity during oral mucosal carcinogenesis: an in vivo experimental study. J Transl Med. 2026; [Crossref]

3- Liu X, Chen Z, Wang X, Yan P, Zong D, Guo W, He X. Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials. iScience. 2025;28(10):113521 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate (2024): 20%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar; SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of
Follower of ICMJE
Permission: Creative Commons